세그먼트, 지리, 역학, 최근 개발 및 전략적 통찰력별 난소암 약물 시장 보고서 2030

  • Report Code : TIPRE00003750
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Ovarian Cancer Drugs Market Trends, Size, Growth by 2030

Buy Now

[연구보고서] 난소암 치료제 시장 규모는 2022년 21억 달러에서 2030년 38억 달러로 성장할 것으로 예상된다. 시장은 2022~2030년에 7.7%의 CAGR을 기록할 것으로 추정됩니다.

시장 통찰력 및 분석가 견해:

난소암 발병률의 증가는 난소암 약물 시장 성장을 촉진합니다. 그러나 부작용으로 인한 제품 리콜은 시장 성장을 저해합니다.

성장 동인:

난소암 발병률 증가로 치료 옵션에 대한 수요 촉진

난소암은 7번째로 많은 암입니다. 여성에게 흔히 발생하는 암이며, 자궁경부암과 자궁내막암에 이어 세 번째로 흔한 부인과 악성종양입니다. 세계난소암연합(World Ovarian Cancer Coalition) 보고서에 따르면, 매년 324,000명의 여성이 난소암 진단을 받고, 207,000명의 여성이 이 질병으로 사망합니다. 또한, 난소암 조기 발견을 위한 공중 보건 검진 프로그램이 없기 때문에 난소암 환자의 대다수는 진행성 단계(국소 진행성 또는 전이성) 상태로 진단됩니다. 따라서 난소암 발병률이 증가함에 따라 효과적인 치료 옵션에 대한 요구가 높아지고 있습니다. 용적축소 수술과 백금 기반 화학요법을 결합한 1차 치료법은 새로 진단된 진행성 난소암 여성을 위한 표준 치료법입니다. 또한 승인된 PARP 억제제, 올라파립, 루카파립, 니라파립과 같은 치료 옵션은 새로 진단된 난소암 관리를 위한 획기적인 옵션입니다. 진행성 난소암 관리에 PARP 억제제를 사용하는 것도 임상 결과를 개선하기 위한 효과적인 치료 옵션으로 떠오르고 있습니다. 이들 억제제는 1차, 2차, 3차 백금 기반 화학요법에 대한 완전 반응(CR) 후 새로 진단된 사례에서 장기 효능과 무진행 생존(PFS)을 제공합니다.

< br>
보고서 세분화 및 범위:

난소암 치료제 시장 분석은 유형, 약물 종류 및 유통 채널과 같은 세그먼트를 고려하여 수행되었습니다.

세그먼트 분석:

유형별로 시장은 상피성 난소암, 생식세포 난소암, 간질종양으로 분류됩니다. 상피성 난소암 부문은 2022년에 가장 큰 난소암 치료제 시장 점유율을 차지했습니다. 동일한 부문은 예측 기간 동안 8.2%의 가장 높은 CAGR을 기록할 것으로 예상됩니다. Cancer Research UK 보고서에 따르면 상피성 난소암은 난소암의 가장 흔한 유형입니다. 예를 들어, 난소 종양 100개 중 거의 90개(90%)가 상피 종양입니다. 공격적인 말기 난소암 환자는 시장에서 이용 가능한 치료 옵션이 제한되어 있습니다. 2022년 11월, 식품의약국(FDA)은 상피성 난소암으로 고통받는 성인 환자를 위해 Elahere ImmunoGen, Inc.가 제조한 "mirvetuximab soravtansine-gynx"에 대한 승인을 발표했습니다. 상피성 난소암 치료를 위한 이 약물 후보의 의사 권장 용량은 6mg/kg이며, 3주에 한 번씩 IV 주입으로 투여됩니다. 지난 2024년 1월, FDA는 재발성 상피성 난소암 환자 치료를 위한 메조텔린 표적 항체-약물 접합체(ADC)인 'RC88'에 대해 신속지정(FTD) 승인을 발표했다. 따라서 약물 승인 수가 증가함에 따라 상피성 난소암 부문의 난소암 약물 시장이 촉진되고 있습니다.

유형별 난소암 약물 시장 – 2022년 및 2030년

난소암 약물 시장 동향

병용 약물 치료

여러 의학 연구 기관에서 난소암 치료를 위한 새로운 복합 약물을 개발하고 있습니다. 2023년 9월, Royal Marsden의 연구원들은 진행성 난소암 환자에게 효과적인 것으로 입증된 새로운 약물 병용 요법을 발표했습니다. 연구자들은 치료에 대한 반응률이 낮은 희귀한 형태의 난소암인 저등급 장액성 난소암(LGSOC)에 대한 효과를 알아보기 위해 병용 약물 요법을 테스트했습니다. RAMP-201 임상시험은 아부토메티닙과 디팩티닙을 병용해 LGSOC 환자를 대상으로 시너지 치료 효과를 조사하는 방식으로 진행됐다. 중간 임상시험 결과에 따르면, 병용요법으로 치료받은 환자의 45%가 종양이 크게 감소한 것으로 나타났습니다. 이처럼 병용요법으로 만족스러운 임상 결과를 얻은 것은 영국의 표적치료제인 트라메티닙(반응률 26%)에 비해 거의 2배에 가까운 효과다. 2024년 1월, FDA는 유방암 및 난소암 환자 치료를 위한 SH-105 복합제의 승인을 발표했습니다. 따라서 복합 약물 요법은 향후 난소암 약물 시장 성장을 촉진할 가능성이 있는 새로운 트렌드로 떠오르고 있습니다.

지역 분석:

난소암 약물 시장 보고서 범위 북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카가 포함됩니다. 2022년에는 북미가 난소암 치료제 시장 점유율 1위를 차지했습니다. 이 지역의 시장 성장은 상위 기업의 제품 출시 증가와 주요 시장 참가자의 존재에 의해 주도됩니다. 미국은 북미 시장에 가장 큰 기여를 하고 있습니다. 여성의 난소암 발생률이 증가함에 따라 기업과 규제 기관은 이 지역에서 각각 혁신적인 약물을 개발하고 승인해야 합니다. 또한 계약 임상 연구 기관(CRO)의 수가 증가함에 따라 북미 난소암 약물 시장의 성장이 촉진되었습니다.

업계 발전 및 미래 기회:

난소암 약물 시장 예측 이 시장의 이해관계자가 성장 전략을 계획하는 데 도움이 될 수 있습니다. 시장에서 활동하는 주요 기업의 몇 가지 전략적 개발은 다음과 같습니다.

... 2022년 11월 ImmunoGen은 백금에 내성이 있는 성인 환자 치료를 위해 ELAHERE(mirvetuximab soravtansine-gynx)에 대해 FDA 승인을 받았습니다. 저항성 상피성 난소암. ELAHERE는 FRα 양성 백금 내성 난소암 환자를 위해 특별히 승인되었습니다. 이는 제한된 치료 옵션의 가용성과 기존 치료법의 열악한 임상 결과로 인해 어려운 상태입니다.경쟁 환경 및 주요 회사:

Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen(AbbVie), GeneTech(Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris 및 Luye Pharma는 난소암 약물 시장 보고서에 소개된 저명한 회사 중 하나입니다. 이들 회사는 전 세계적으로 증가하는 소비자 수요를 충족시키기 위해 새로운 기술을 개발하고, 기존 제품을 업그레이드하며, 지리적 입지를 확장하는 데 중점을 두고 있습니다.
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is the market CAGR value of ovarian cancer drugs market during forecast period?

The CAGR value of the ovarian cancer drugs market during the forecasted period of 2022-2030 is 7.7%.

Which type segment leads the ovarian cancer drugs market?

The epithelial ovarian cancer segment held the largest share of the market in the global ovarian cancer drugs market and held the largest market share in 2022.

What is ovarian cancer drugs market?

Ovarian cancer is a growth of cells that is formed in the ovaries where the cells can multiply quickly and invade destroying the healthy body tissues. Therefore, rising prevalence of ovarian cancer among women enhances therapeutic option and drugs.

Which drug class segment held the largest share in the ovarian cancer drugs market?

The PARP inhibitors segment dominated the global ovarian cancer drugs market and held the largest market share in 2022.

Who are the key players in the ovarian cancer drugs market?

The ovarian cancer drugs market majorly consists of the players such Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma, and amongst others.

Which region is expected to witness significant demand for ovarian cancer drugs market in the coming years?

Global ovarian cancer drugs market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. North America held the largest market share of the ovarian cancer drugs market in 2022.

Which are the top companies that hold the market share in ovarian cancer drugs market?

Elli Lilly and GeneTech (Roche) are the top two companies that hold huge market shares in the ovarian cancer drugs market.

The List of Companies - Ovarian Cancer Drugs Market

  1. Elli Lilly
  2. AstraZeneca
  3. GSK
  4. Zielab
  5. ImmunoGen
  6. GeneTech (Roche)
  7. Vivesto
  8. Allarity Therapeutics, Inc.
  9. Aeterna Zentaris
  10. Luye Pharma

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..